Almirall SA 2023 AR2
The report outlines Almirall S.A.'s financial and operational performance for the fiscal year 2023, highlighting growth in European dermatological sales driven by products like Ilumetri, Wynzora, and Klisyri. It notes key R&D milestones, including the EMA approval of Lebrikizumab (Ebglyss) for atopic dermatitis and new partnerships with Absci and Etherna. The company successfully executed a capital increase of 197.8 million euros and proposed a Scrip Dividend for shareholders. Additionally, the report outlines risk factors, financial risk management strategies, and corporate governance updates.
Company: Almirall SA
Sector: Manufacturing
Country: Spain
Year: 2023
Type: AR2
Pages: 9
Back to company
Almirall SA
Consolidated Management Report
The report outlines Almirall S.A.'s financial and operational performance for the fiscal year 2023, highlighting growth in European dermatological sales driven by products like Ilumetri, Wynzora, and Klisyri. It notes key R&D milestones, including the EMA approval of Lebrikizumab (Ebglyss) for atopic dermatitis and new partnerships with Absci and Etherna. The company successfully executed a capital increase of 197.8 million euros and proposed a Scrip Dividend for shareholders. Additionally, the report outlines risk factors, financial risk management strategies, and corporate governance updates.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
No data available